دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
In the Literature
Stan Deresinski
doi : 10.1093/cid/ciac930
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages i–ii
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019
Sarju Ganatra, Sourbha S Dani, Javaria Ahmad, Ashish Kumar, Jui Shah, George M Abraham, Daniel P McQuillen, Robert M Wachter, Paul E Sax
doi : 10.1093/cid/ciac673
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 563–572
Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus ritonavir (NMV-r) in high-risk nonhospitalized unvaccinated patients reduced the risk of progression to severe disease. However, the potential benefits of NMV-r among vaccinated patients are unclear.
Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment
Brian P Epling, Joseph M Rocco, Kristin L Boswell, Elizabeth Laidlaw, Frances Galindo, Anela Kellogg, Sanchita Das, Allison Roder, Elodie Ghedin, Allie Kreitman, Robin L Dewar, Sophie E M Kelly, Heather Kalish, Tauseef Rehman, Jeroen Highbarger, Adam Rupert, Gregory Kocher, Michael R Holbrook, Andrea Lisco, Maura Manion, Richard A Koup, Irini Sereti
doi : 10.1093/cid/ciac663
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 573–581
Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by coronavirus disease 2019 (COVID-19) but has been associated with symptomatic rebound after therapy completion.
Shared Decision-Making Concerning Anal Cancer Screening in Persons With Human Immunodeficiency Virus
Edward R Cachay, Tari Gilbert, Robert Deiss, Wm Christopher Mathews
doi : 10.1093/cid/ciac491
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 582–591
Anal high-grade squamous intraepithelial lesion (aHSIL) is the immediate precursor of anal cancer. Anal cytology is a recommended screening test to identify aHSIL among people with human immunodeficiency virus (HIV; PWH).
Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras
Jake Sheraj Jacob, Anjiya Shaikh, Karthik Goli, Nicole E Rich, Jihane N Benhammou, Aijaz Ahmed, Donghee Kim, Abbas Rana, John A Goss, Susanna Naggie, Tzu-Hao Lee, Fasiha Kanwal, George Cholankeril
doi : 10.1093/cid/ciac821
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 592–599
People with human immunodeficiency virus (HIV) with and without hepatitis C virus (HCV) coinfection had poor outcomes after liver transplant (LT).
Effect of Malaria and Malaria Chemoprevention Regimens in Pregnancy and Childhood on Neurodevelopmental and Behavioral Outcomes in Children at 12, 24, and 36 Months: A Randomized Clinical Trial
Paul Bangirana, Andrea L Conroy, Robert O Opoka, Margaret Semrud-Clikeman, Jeong H Jang, Claire Apayi, Abel Kakuru, Mary K Muhindo, Michael K Georgieff, Grant M Dorsey, Moses R Kamya, Diane Havlir, Chandy C John
doi : 10.1093/cid/ciac815
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 600–608
Malaria in pregnancy has been associated with worse cognitive outcomes in children, but its association with behavioral outcomes and the effectiveness of malaria chemoprevention on child neurodevelopment are not well characterized.
A Systematic Review of Human Challenge Trials, Designs, and Safety
Jupiter Adams-Phipps, Danny Toomey, Witold Więcek, Virginia Schmit, James Wilkinson, Keller Scholl, Euzebiusz Jamrozik, Joshua Osowicki, Meta Roestenberg, David Manheim
doi : 10.1093/cid/ciac820
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 609–619
Few studies have assessed participant safety in human challenge trials (HCTs). Key questions regarding HCTs include how risky such trials have been, how often adverse events (AEs) and serious adverse events (SAEs) occur, and whether risk mitigation measures have been effective.
Strategies for Using Antigen Rapid Diagnostic Tests to Reduce Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Low- and Middle-Income Countries: A Mathematical Modelling Study Applied to Zambia
Alvin X Han, Sarah J Girdwood, Shaukat Khan, Jilian A Sacks, Amy Toporowski, Naushin Huq, Emma Hannay, Colin A Russell, Brooke E Nichols
doi : 10.1093/cid/ciac814
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 620–630
Increasing the availability of antigen rapid diagnostic tests (Ag-RDTs) in low- and middle-income countries (LMICs) is key to alleviating global SARS-CoV-2 testing inequity (median testing rate in December 2021–March 2022 when the Omicron variant was spreading in multiple countries: high-income countries = 600 tests/100 000 people/day; LMICs = 14 tests/100 000 people/day).
Nosocomial Malaria Transmissions Resolved by Genomic Analyses—A Retrospective Case Report Study in France: 2007–2021
Romain Coppée, Véronique Sarrasin, Rizwana Zaffaroulah, Azza Bouzayene, Marc Thellier, Harold Noël, Jérôme Clain, Sandrine Houzé, the Investigation Study Group
doi : 10.1093/cid/ciac813
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 631–639
Exposure of blood to malaria parasites can lead to infection even in the absence of the mosquito vector. During a stay in a healthcare facility, accidental inoculation of the skin with blood from a malaria patient might occur, referred to as nosocomial malaria.
Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study
Sharifa Nasreen, Yossi Febriani, Héctor Alexander Velásquez GarcÃa, Geng Zhang, Mina Tadrous, Sarah A Buchan, Christiaan H Righolt, Salaheddin M Mahmud, Naveed Zafar Janjua, Mel Krajden, Gaston De Serres, Jeffrey C Kwong
doi : 10.1093/cid/ciac634
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 640–648
A major goal of coronavirus disease 2019 (COVID-19) vaccination is to prevent severe outcomes (hospitalizations and deaths). We estimated the effectiveness of messenger RNA (mRNA) and ChAdOx1 COVID-19 vaccines against severe outcomes in 4 Canadian provinces between December 2020 and September 2021.
Association of Antibody Immunity With Cryptococcal Antigenemia and Mortality in a South African Cohort With Advanced Human Immunodeficiency Virus Disease
Hyunah Yoon, Rachel M Wake, Antonio S Nakouzi, Tao Wang, Ilir Agalliu, Caroline T Tiemessen, Nelesh P Govender, Joseph N Jarvis, Thomas S Harrison, Liise-anne Pirofski
doi : 10.1093/cid/ciac633
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 649–657
Asymptomatic cryptococcal antigenemia (positive blood cryptococcal antigen [CrAg]) is associated with increased mortality in individuals with human immunodeficiency virus (HIV) even after adjusting for CD4 count and despite receiving antifungal treatment. The association of antibody immunity with mortality in adults with HIV with cryptococcal antigenemia is unknown.
Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Detection by Lateral Flow Immunoassay
Christina J Atchison, Maya Moshe, Jonathan C Brown, Matthew Whitaker, Nathan C K Wong, Anil A Bharath, Rachel A McKendry, Ara Darzi, Deborah Ashby, Christl A Donnelly, Steven Riley, Paul Elliott, Wendy S Barclay, Graham S Cooke, Helen Ward
doi : 10.1093/cid/ciac629
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 658–666
We explore severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow immunoassay (LFIA) performance under field conditions compared to laboratory-based electrochemiluminescence immunoassay (ECLIA) and live virus neutralization.
Spatiotemporal Trends in Norovirus Outbreaks in the United States, 2009–2019
Anita K Kambhampati, Laura Calderwood, Mary E Wikswo, Leslie Barclay, Claire P Mattison, Neha Balachandran, Jan Vinjé, Aron J Hall, Sara A Mirza
doi : 10.1093/cid/ciac627
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 667–673
Globally, noroviruses cause infections year-round but have recognized winter seasonality in the Northern Hemisphere and yearly variations in incidence. With candidate norovirus vaccines in development, understanding temporal and geographic trends in norovirus disease is important to inform potential vaccination strategies and evaluate vaccine impact.
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer
Johan Maertens, Tom Lodewyck, J Peter Donnelly, Sylvain Chantepie, Christine Robin, Nicole Blijlevens, Pascal Turlure, Dominik Selleslag, Frédéric Baron, Mickael Aoun, Werner J Heinz, Hartmut Bertz, Zdeněk Rá�il, Bernard Vandercam, Lubos Drgona, Valerie Coiteux, Cristina Castilla Llorente, Cornelia Schaefer-Prokop, Marianne Paesmans, Lieveke Ameye, Liv Meert, Kin Jip Cheung, Deborah A Hepler, Jürgen Loeffler, Rosemary Barnes, Oscar Marchetti, Paul Verweij, Frederic Lamoth, Pierre-Yves Bochud, Michael Schwarzinger, Catherine Cordonnier, for the Infectious Diseases Group and the Acute Leukemia Group of the European Organization for Research and Treatment of Cancer
doi : 10.1093/cid/ciac623
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 674–682
Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown.
Efficacy of Doxycycline for Mild-to-Moderate Community-Acquired Pneumonia in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Sang-Ho Choi, Antoni Cesar, Timothy Arthur Chandos Snow, Naveed Saleem, Nishkantha Arulkumaran, Mervyn Singer
doi : 10.1093/cid/ciac615
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 683–691
Doxycycline has been recommended as a treatment option for non-severe community-acquired pneumonia (CAP) in adults. We sought to review the evidence for the efficacy of doxycycline in adult patients with mild-to-moderate CAP.
Doxycycline to Treat Community-Acquired Pneumonia
Daniel M Musher
doi : 10.1093/cid/ciac617
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 692–693
Pneumonia, Meningitis, and Septicemia in Adults and Older Children in Rural Gambia: 8 Years of Population-Based Surveillance
Edward W Green, Malick Ndiaye, Ilias M Hossain, Yekini A Olatunji, Shah M Sahito, Rasheed Salaudeen, Henry Badji, Ahmed Manjang, Lamin Ceesay, Philip C Hill, Brian Greenwood, Grant A Mackenzie
doi : 10.1093/cid/ciac603
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 694–703
Representative data describing serious infections in children aged ≥5 years and adults in Africa are limited.
Malaria Transmission Dynamics in a High-Transmission Setting of Western Kenya and the Inadequate Treatment Response to Artemether-Lumefantrine in an Asymptomatic Population
Ben Andagalu, Oliver J Watson, Irene Onyango, Benjamin Opot, Raphael Okoth, Gladys Chemwor, Peter Sifuna, Dennis Juma, Agnes Cheruiyot, Redemptah Yeda, Charles Okudo, Jackline Wafubwa, Santos Yalwala, David Abuom, Bernhards Ogutu, Jessica Cowden, Hoseah M Akala, Edwin Kamau
doi : 10.1093/cid/ciac527
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 704–712
Assessing the infectious reservoir is critical in malaria control and elimination strategies. We conducted a longitudinal epidemiological study in a high-malaria-burden region in Kenya to characterize transmission in an asymptomatic population.
A Retrospective Database Analysis of Before and After Social Distancing in Relation to Pediatric Infection Rate and Healthcare Services Usage During the Coronavirus Disease 2019 Pandemic
Ran Levy, Regev Cohen, Liat Lev-Shalem, Arik Eisenkraft, Tehila Fisher Yosef
doi : 10.1093/cid/ciac502
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 713–719,
Social distancing policy was introduced in Israel in 2020 to reduce the spread of coronavirus disease 2019 (COVID-19). The aim of this study was to analyze the effect of social distancing on other infections in children, by comparing disease rate and healthcare utilization before and after social distancing.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Josep M Llibre, Carlos Brites, Chien-Yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Stephen Taylor, Elizabeth Blair, Choy Man, Brian Wynne, James Oyee, Mark Underwood, Lloyd Curtis, Gilda Bontempo, Jean van Wyk
doi : 10.1093/cid/ciac130
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 720–729
In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-term noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment-experienced adults with HIV-1. The phase 3 SALSA study evaluated efficacy and safety of switching to DTG/3TC compared with continuing various 3-/4-drug current antiretroviral regimens (CARs).
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection
Eveline Hofmann, Bernard Surial, Noémie Boillat-Blanco, Huldrych F Günthard, Marcel Stöckle, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, Franziska Suter-Riniker, Andri Rauch, Gilles Wandeler, Charles Béguelin, for the Swiss HIV Cohort Study
doi : 10.1093/cid/ciac823
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 730–733
In the Swiss HIV Cohort Study, 61 of 222 (27%) HIV–suppressed persons with chronic hepatitis B virus (HBV) infection had HBV replication after 2 years on tenofovir, of whom 77% were suppressed thereafter. Self-reported adherence to therapy and HBV viral load at tenofovir initiation were predictors of persistent replication.
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019
Yijia Li, Linda J Harrison, Kara W Chew, Judy S Currier, David A Wohl, Eric S Daar, Teresa H Evering, Ryan Wu, Mark Giganti, Justin Ritz, Arzhang Cyrus Javan, Robert W Coombs, Carlee Moser, Michael D Hughes, Joseph J Eron, Davey M Smith, Jonathan Z Li
doi : 10.1093/cid/ciac818
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 734–737
Acute Coronavirus Disease 2019 symptoms limit daily activities, but little is known about its association with severe acute respiratory syndrome coronavirus 2 viral burden.
Reduced Incidence of Long Coronavirus Disease Referrals to the Cambridge University Teaching Hospital Long Coronavirus Disease Clinic
Benjamin A Krishna, Marina Metaxaki, Mark R Wills, Nyaradzai Sithole
doi : 10.1093/cid/ciac630
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 738–740
Long coronavirus disease (COVID [LC]) constitutes a potential health emergency as millions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections lead to chronic symptoms.
Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine
Ralph Rogers, Peter J Krause, Ashlyn M Norris, Michelle H Ting, Ellen H Nagami, Brian Cilley, Edouard Vannier
doi : 10.1093/cid/ciac473
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 741–744
We describe a case of relapsing babesiosis in an immunocompromised patient. A point mutation in the Babesia microti 23S rRNA gene predicted resistance to azithromycin and clindamycin, whereas an amino acid change in the parasite cytochrome b predicted resistance to atovaquone.
Less Is More? Antibiotic Treatment Duration in Pseudomonas aeruginosa Ventilator-Associated Pneumonia
Owen R Albin, Keith S Kaye, Erin K McCreary, Jason M Pogue
doi : 10.1093/cid/ciac784
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 745–749
Recommended antimicrobial treatment durations for ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa have evolved over the past few decades.
Less Is More: A 7-Day Course of Antibiotics Is the Evidence-Based Treatment for Pseudomonas aeruginosa Ventilator-Associated Pneumonia
Mark L Metersky, Michael Klompas, Andre C Kalil
doi : 10.1093/cid/ciac809
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 750–752
The Coronavirus Disease 2019 Pandemic Unmasked the Challenges Faced by Early-Stage Faculty in Infectious Diseases: A Call to Action
Erin M Scherer, Martin Backer, Karen Carvajal, Lara Danziger-Isakov, Sharon Frey, Leigh M Howard, Felicia Scaggs Huang, Angelica C Kottkamp, Tara Reid, Maria C Rodriguez-Barradas, Helen C Stankiewicz Karita, Zheyi Teoh, Anna Wald, Jennifer Whitaker, Zanthia Wiley, Igho Ofotokun, Kathryn M Edwards, for the Infectious Diseases Clinical Research Consortium (IDCRC) Mentorship Program Writing Group
doi : 10.1093/cid/ciac779
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 753–759
The coronavirus disease 2019 (COVID-19) pandemic and associated increase in family care responsibilities resulted in unsustainable personal and professional workloads for infectious diseases (ID) faculty on the front lines.
A Fatal Hand Laceration
Amna Ahmed, Jonathan Lockhart, Kenneth L Muldrew, Megan Amerson-Brown, Andrew Chou
doi : 10.1093/cid/ciac018
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 760–763
Cryptococcal Antigenemia in Advanced Human Immunodeficiency Virus Disease: Pathophysiology, Epidemiology, and Clinical Implications
Rachel M Wake, SÃle F Molloy, Joseph N Jarvis, Thomas S Harrison, Nelesh P Govender
doi : 10.1093/cid/ciac675
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 764–770
Safety of Dengue Vaccine?
Shibadas Biswal, Sanjay S Patel, Martina Rauscher
doi : 10.1093/cid/ciac808
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 771–772
A Shorter Time to Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Redefining Beta-Lactam–Associated DRESS
Jamie L Waldron, Fiona James, Sara Vogrin, Kyra Y L Chua, Natasha E Holmes, Joseph DeLuca, Michelle S Goh, Abby P Douglas, Jason A Trubiano
doi : 10.1093/cid/ciac798
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 772–774
The Confounding Effect of Vaccine Status
Chi-Kuei Hsu, Chih-Cheng Lai
doi : 10.1093/cid/ciac770
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Page 774
Reply to Authors
Sarju Ganatra, Sourbha S Dani, Paul E Sax
doi : 10.1093/cid/ciac771
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 774–775
Usage and Awareness of Antiviral Medications for Coronavirus Disease 2019 (COVID-19) Among Individuals at Risk for Severe COVID-19, March 2021 to 1 August 2022
Noah Kojima, Jeffrey D Klausner
doi : 10.1093/cid/ciac743
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 775–776
Correction to: Stopping Hospital Infections With Environmental Services (SHINE): A Cluster-randomized Trial of Intensive Monitoring Methods for Terminal Room Cleaning on Rates of Multidrug-resistant Organisms in the Intensive Care Unit
doi : 10.1093/cid/ciac919
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Page 777
Correction to: Outbreak of Respiratory Syncytial Virus Bronchiolitis in Italy
doi : 10.1093/cid/ciac908
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 777–779
Correction to: Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial
doi : 10.1093/cid/ciac768
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Page 778
Correction to: Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
doi : 10.1093/cid/ciac584
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Pages 778–779
Correction to: Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective
doi : 10.1093/cid/ciac306
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Page 779
Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
doi : 10.1093/cid/ciac347
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Page 779
Retraction: Errors of Interpretation - Correcting the Record on the Comparative Efficacy of Surgical Masks Versus Respirators
doi : 10.1093/cid/ciad007
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Page 781
Retraction of “Voluntary Medical Male Circumcision� by Brian Morris
doi : 10.1093/cid/ciab322
Clinical Infectious Diseases, Volume 76, Issue 4, 15 February 2023, Page 785
